CDT Equity (CDT) Other Non-Current Liabilities (2022 - 2026)
CDT Equity's (CDT) quarterly Other Non-Current Liabilities came in at $773000.0 in Q1 2026, down 90.34% YoY from $8.0 million in Q1 2025, and up 17.12% on a QoQ basis from $660000.0 in Q4 2025.
CDT Equity (CDT) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Other Non-Current Liabilities data on file, last reported at $773000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 90.34% year-over-year to $773000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $773000.0 (down 90.34% YoY) and the FY2025 annual result came in at $660000.0, up 378.26% from the prior year.
- Other Non-Current Liabilities improved to $773000.0 in Q1 2026, from $660000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $8.0 million in Q1 2025 to a low of $1000.0 in Q2 2025.
- A 5-year average of $1.1 million and a median of $119000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 7900.0% in 2025, down 96.88% in 2025.
- Tracing CDT's Other Non-Current Liabilities over 5 years: stood at $3.3 million in 2022, then slumped by 95.63% to $142000.0 in 2023, then slipped by 2.82% to $138000.0 in 2024, then surged by 378.26% to $660000.0 in 2025, then increased by 17.12% to $773000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $773000.0 (Q1 2026), $660000.0 (Q4 2025), and $1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 264,000.00 |
| Mar 31, 2026 | 773,000.00 |
| Dec 31, 2025 | 660,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | 24,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 142,000.00 |
| Sep 30, 2023 | 92,000.00 |
| Dec 31, 2022 | 3.25 Mn |